Structured benefit–risk evaluation for medicinal products: review of quantitative benefit–risk assessment findings in the literature

A favorable benefit–risk profile remains an essential requirement for marketing authorization of medicinal drugs and devices. Furthermore, prior subjective, implicit and inconsistent ad hoc benefit–risk assessment methods have rightly evolved towards more systematic, explicit or “structured” approac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kürzinger, Marie-Laure, Douarin, Ludivine, Uzun, Ievgeniia, El-Haddad, Chantal, Hurst, William, Juhaeri, Juhaeri, Tcherny-Lessenot, Stéphanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727082/
https://www.ncbi.nlm.nih.gov/pubmed/33343857
http://dx.doi.org/10.1177/2042098620976951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727082/
https://www.ncbi.nlm.nih.gov/pubmed/33343857
http://dx.doi.org/10.1177/2042098620976951

Ejemplares similares